

VOLUME 276 • NUMBER 2 • FEBRUARY 1996

JPETAB 276 (2) 353-865 (1996)

ISSN 0022-3565

**The Journal of**  
**PHARMACOLOGY**  
**AND EXPERIMENTAL THERAPEUTICS**

*A Publication of The American Society  
for Pharmacology and Experimental Therapeutics  
Founded by John J. Abel—1909*

Edited for the Society by John A. Harvey




Published by Williams & Wilkins



# MICRODIALYSIS INSTRUMENTS

- Basic, cost-effective and advanced, computer-controlled systems
- Precision pumps, liquid switches, probes and microfraction collectors
- Application Notes, Microdialysis Training Courses and Instrument Service



Our shelves are fully stocked with the complete line of Microdialysis equipment and supplies.  
In fact most probes and accessories are available to be shipped to you overnight.  
Build or update your microdialysis system to suit your individual needs.

If your future plans include the expansion of microdialysis capabilities,  
or need for Technical Support or Instrument Service

Call Toll-free: (800) 440-4980

or send us a fax today!

**CMA** *Microdialysis*

**COPYRIGHT © 1996 BY THE AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS**



SUBCUTANEOUS SPACE

SPINAL CORD

RENAL ARTERY

PERITONEAL CAVITY

SOLEUS MUSCLE

SPLEEN

CEREBRAL VENTRICLES

JUGULAR VEIN

BONE

## THINK GLOBALLY. TARGET LOCALLY.


Whether you're looking at whole systems or local phenomena, the new Model 2004 ALZET<sup>®</sup> osmotic pump helps you observe the in vivo effects of compounds more accurately.

This miniature, implantable pump continuously delivers your test agents for four weeks, at a rate of 0.25  $\mu$ l/hr. Its small size, long duration, and low flow rate make the Model 2004 ideal for brain infusion or targeted delivery in mice and rats.

ALZET pumps offer more accurate in vivo delivery. By sustaining compound levels in plasma and tissues, they allow the effects of your agent to develop fully and reproducibly. ALZET pumps have successfully delivered hundreds of agents – including proteins and other short half-life compounds. Using a simple catheter attachment, you can localize delivery to specific areas. And operation is fully automatic, eliminating the need for complicated dosing schedules.

Look at drug delivery from a new perspective. Call ALZET Technical Services at (800) 524-0095 or (415) 962-2251. Specify your region of interest, and we'll send an information package that will reveal a world of possibilities.

**alzet**<sup>®</sup>  
OSMOTIC PUMPS





# Notice to Contributors (Revised July 1, 1994)

## Scope of Submitted Manuscripts

The Journal invites for review original papers dealing with interactions of chemicals with biological systems. Any aspect of pharmacology and therapeutics is included, but descriptive case reports without dose response or mechanism studies are not accepted. Manuscripts dealing primarily with new methods will be reviewed only if data are presented showing new or more reliable pharmacological information has been obtained by use of the methods.

## Submission of Manuscripts

Submit four copies of manuscript to **Dr. John A. Harvey, Editor in Chief, Journal of Pharmacology and Experimental Therapeutics, Medical College of Pennsylvania and Hahnemann University, EPPI Conference Center, Suite 505D, 3200 Henry Avenue, Philadelphia, PA 19129**, accompanied by a check or purchase order for **\$40.00 manuscript handling fee** (in U.S. funds drawn on a U.S. bank payable to ASPET). If submission of the manuscript handling fee entails personal financial hardship to the author, the fee will be waived. In that event the authors should submit a request for waiver of the fee at the time the manuscript is submitted. Only one copy of rejected manuscripts will be returned. Extra copies of figures will not be returned unless specifically requested at the time the manuscript is submitted.

Manuscripts should be typewritten and double spaced in the English language using one side only of approximately 21.6 by 28 cm paper. One original drawing or photograph of each line figure and four (4) clear copies and/or 4 original drawings or photographs of each halftone figure are required. Pages should not be stapled together.

Authors submitting a manuscript do so with the understanding that if it is accepted for publication, copyright in the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to the Society for Pharmacology and Experimental Therapeutics. Reasonable requests by authors for permission to reproduce their contributions to the Journal will not be refused. It will be necessary for all authors to sign an assignment of copyright form which will be mailed from the Editorial Office on acceptance of the manuscript. The only exceptions will be manuscripts on work performed by employees of the U.S. Federal Government.

## Cover Letter

**Each manuscript must be accompanied by a written statement signed by one author:** "The undersigned author affirms that the manuscript (title of article) and the data it contains are original, are not under consideration by another journal, and have not been published previously. The studies reported in this manuscript have been carried out in accordance with the Declaration of Helsinki and/or with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the National Institute of Health". Authors should also indicate in the cover letter the field of pharmacology to which the research applies.

## Organization of the Manuscript

In most cases manuscripts should contain the following sections in the order listed; each section should begin on a new page and all pages should be numbered consecutively.

**1. Title page.** This should contain the complete title of the manuscript, the names of all authors, and the laboratory of origin. Support for the research should be indicated as a numbered footnote to the title and included with other footnotes on a separate page following the reference section.

**2. Running title page.** a) A running title: should be included at the top of this page and should contain no more than 35 spaces, including punctuation. It should convey the sense of the full title. Commonly used abbreviations (such as "ATP," "ACh," etc.) may be used in the running title. b) Corresponding author: this page should also contain the name, address, telephone and fax number of the person to whom all correspondence should be sent. c) A list of abbreviations used in the paper should also appear on this page. Additionally, each abbreviation should be defined the first time it is used in the text.

**3. Abstract.** The abstract should present in a concise form the purpose, the general methods, the findings, and the conclusions of the manuscript. Abstracts should be limited to 200

words; abstracts of more than 250 words will not be accepted.

**4. Introduction.** This section should not be labeled, but should begin on a new page. It should contain a clear statement of the aims of the reported work or of the hypotheses which the work was designed to test. A brief account of the background of the reported work may also be given in this section.

**5. Methods.** This section should contain explicit, concise descriptions of all new methods or procedures employed. Modifications of previously published methods should be described. Commonly used methods require only a citation of the original source. When methods are described, the description should be such as to enable the reader to judge their accuracy, reproducibility and reliability and to repeat the experiment. Very extended descriptions of methods may be submitted for deposit with the American Society for Information Science National Auxiliary Publications Service (NAPS) c/o Microfiche Publications, P.O. Box 3513, Grand Central Station, New York, NY 10017. A text reference or footnote stating that the full description is available from NAPS permits interested readers to obtain the information and does not occupy an inordinate amount of Journal space. There is a nominal charge to authors for this procedure; those who request the complete information from NAPS pay a small fee.

**6. Results.** This section ordinarily contains the experimental data to be presented, but not extended discussions of their significance. Results should usually be presented in graphic or tabular form, rather than discursively. Graphic presentation of data is often preferred but there should not be duplication in text, tables and figures. Sufficient data must be given to allow readers to judge the variability and reliability of the results. Statistical tests used and the data analyzed should be explained so that the findings can be interpreted and evaluated.

**7. Discussion.** This section should present conclusions to be drawn from the results. Speculative discussion is not discouraged, but the speculation should be based on the data presented and identified as such. The discussion should be as concise as possible, within the limits of the ideas which the authors wish to propose and adequate discussion of related work by others.

**8. Acknowledgments.** This section should begin on a separate page, have a separate heading, and be placed at the end of the text of the manuscript. Gifts and assistance can be acknowledged here but, financial support should appear in a footnote to the title.

**9. References.** In text citations give the author's name and the year of publication (e.g., McCarthy, 1952; Ruth and Gehrig, 1929). With more than two authors, the text citation should contain the name of the first author, followed by "et al.," and the date (e.g., Kennedy et al., 1960). In the list of references, entries should be arranged alphabetically by author and not numbered. All authors' names should be given. If reference is made to more than one publication by the same authors in the same year, suffixes (a, b, c, etc.) should be added to the year in the text citation and in the list of references.

The list of references should contain, in sequence, the following information: authors' names and initials, title of the cited article, title of the journal in which it appeared, volume number of the journal, inclusive pagination and year of publication. Abbreviations for journals should conform to the Biosis List of Serials (BioSciences Information Services of Biological Abstracts, Philadelphia, PA 19103). Citations of personal communications, unpublished observations, and papers submitted for publication should be given in parentheses at the appropriate place in the text, not in the list of references. A paper may not be cited as "in press" unless it has been accepted for publication. In such cases the name of the journal must be given.

Examples of references to books, chapters and journal articles follow:

Bruce, M. S.: The anxiogenic effects of caffeine. *Postgrad. Med. J.* 66: 18-24, 1990.

Griffiths, R. R., Bigelow, G. E. and Liebson, I. A.: Human Coffee drinking: Reinforcing and physical dependence producing effects of caffeine. *J. Pharmacol. Exp. Ther.* 239: 416-425, 1986.

Tallarida, R. J. and Murray, R. B.: *Manual of Pharmacologic*

Calculations with Computer Programs. Springer-Verlag, New York, 1987.

Young, A. M. and Sannerud, C. A.: Tolerance to drug discriminative stimuli. In *Psychoactive Drugs: Tolerance and Sensitization*, ed. by A. J. Goudie and M. W. Emmett-Oglesby, pp. 221-270, Humana Press, Clifton, NJ, 1989.

No more than four references should be cited in support of any given point. The authors are responsible for accuracy of such citations and are urged to take the utmost care in proofreading citations and the reference list.

**10. Footnotes.** All footnotes to the title, authors' names or text should be indicated by arabic numeral superscripts, not by letters or other symbols. The footnotes should be typed in sequence on a separate page, not a text page. Footnotes to tables are discussed under Tables, below.

**11. Tables.** Each table should be on a separate page. Tables should be numbered consecutively with arabic numerals, and should be designed to fit the column or page size of the Journal. A brief descriptive title should be given at the top of each table. The table number should be given in capital letters, the title in boldface upper and lower case letters (*e.g.*, TABLE 3. **Uptake of labeled drug by rat liver slices**). The footnotes to the tables should be referenced by italicized lower case superscript letters (*a*, *b*, *c*, etc.) and should appear beneath the table involved, not on a separate page of the manuscript. Extensive tabular material not absolutely essential to the manuscript will be accepted for deposit with the ASIS/NAPS (see "Methods," above). In such instances a footnote in the published paper will refer the interested readers to NAPS from which copies may be obtained. Note *Statistics* below for expressions of probability.

**12. Legends for figures.** These should be numbered consecutively in arabic numerals and should appear on a separate page of the manuscript. Legends should explain the figures in sufficient detail so that frequent referral to the text is unnecessary, but efforts should be made to avoid unnecessary length. Abbreviations in the legends should conform to those in the text (see "Abbreviations," below).

**13. Figures.** Illustrations should be submitted as unmounted glossy prints, or laser jet quality figures, preferably reduced to single column size (approximately 3½ inches in width) to permit reproduction without further reduction. Otherwise, prints should be no larger than 8 by 10 inches and clear enough to permit reproduction without retouching after reduction. The author's name and address and the number of the figure should be placed on the back of each print. A typed label is usually most satisfactory. Ball type pen should not be used. Note *Statistics* below for expression of probability. Uniform symbolism should be used for all illustrations in a manuscript. Symbols, numbers, and letters in the illustrations must be at least 1.5mm in height after reduction to single column size. The title of each figure should appear in the legend rather than on the figure itself. Photomicrographs and electron micrographs should be labeled with a magnification calibration in micro or Angstrom units. A statement of the magnification should appear in the figure legend.

**14. Index Terms.** A list of index terms useful in constructing the annual index should be included as the last page of the manuscript.

## Statistics

Wherever possible statistical probability (*P*) in tables, figures, and figure legends should be expressed as \* *P* < .05, \*\* *P* < .01 and \*\*\* *P* < .001. For second comparisons the symbols † may be used similarly. Authors are urged to avoid unnecessary complexity and to be consistent within the manuscript. In the event of multiple comparisons within a table, footnotes, *a*, *b*, *c*, etc. should be used.

## Abbreviations

Magnitudes of variables reported should be expressed in numerals. Most abbreviations are used without punctuation, with no distinction between singular and plural forms (*e.g.*, 1 mg, 25 mg; 1 sec, 25 sec). The usual prefixes are to be used for multiples or submultiples of the basic units (*e.g.*, kg, g, mg, µg, ng, pg). The following abbreviations, or their properly prefixed multiples or submultiples, may be used without definition in the text, tables and figures:

## Units of mass

gram	g
mole	mol
equivalent	Eq
microatom	µat

## Units of concentration

molar (moles/liter)	M
normal (Eq/liter)	N
percent	%

## Units of length or volume

meter	m
micron	µ
Angstrom	Å
liter (spell out in text)	l

## Kinetics

dissociation constant

*K<sub>d</sub>*

**Dissociation constant of**  
enzyme substrate complex  
enzyme inhibitor complex  
Michaelis constant  
maximum initial velocity

*K<sub>e</sub>*

*K<sub>i</sub>*

*K<sub>m</sub>*

*V<sub>max</sub>*

## Miscellaneous

degrees of temperature

°C

gravity

g

median doses

LD<sub>50</sub>, ED<sub>50</sub>, etc.

optically isometric forms

*d*-, *l*-, *dl*-

routes of drug administration

i.v., i.p., s.c., i.m.

standard deviation

S.D.

standard error

S.E.

Whenever an abbreviation other than those above is to be used in a manuscript, it is to be defined in the text or in a footnote thereto, the first time it is used. Abbreviations for commonly used substances should be those recommended by the Journal of Biological Chemistry. Abbreviations for drugs may be used if properly defined on first use and if the chemical or generic name of the drug is given when the abbreviation is first used. Abbreviations may be used in the running title but not in the full title of the manuscript.

## Drugs

Generic names should be used in text, tables and figures. Trade names may be mentioned in parentheses in the first text reference to the drug but should not appear in titles, figures or tables. When a trade name is used, it should be capitalized; generic or chemical names are not capitalized. The chemical nature of new drugs must be given when it is known. The form of drug used in calculations of doses (*e.g.*, base or salt) should be indicated. When several drugs are used, it may save space to include a separate paragraph in "Methods," or a separate table or footnote, listing the relevant information about all drugs employed.

## Page Charges

Authors are assessed page charges at the rate of \$30 per printed page. With the page proof, authors will receive a request for information concerning such charges. These charges will be assessed only if they involve no personal expense to the authors. Request for waiver should be addressed to the ASPET Executive Officer at the time billing is received.

The cost of a limited number of illustrations will be borne by the Journal; the cost of excessive illustrations and of colored illustrations will have to be defrayed by the authors.

**After acceptance:** When the field editor recommends acceptance of an article for publication, authors are encouraged to submit electronic diskettes of the final version along with the typed REVISED manuscript. The author will receive a packet of information containing copyright forms and detailed instructions pertaining to the publication of their manuscript.

**Reprints and page charges.** An order form for reprints as well as information on the estimation of page charges will be mailed with the galley proof. Please direct questions on page charges, or other business matters to Kay Croker, Executive Officer, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814.

## INFORMATION FOR SUBSCRIBERS

**THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS** (ISSN 0022-3565) is an official publication of The American Society for Pharmacology and Experimental Therapeutics and is published by Williams & Wilkins, 351 West Camden Street, Baltimore, MD 21201-2436. Second class postage paid at Baltimore, MD and at additional mailing offices. POSTMASTER: Send address changes to THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 351 West Camden Street, Baltimore, MD 21201-2436.

**Frequency:** *Monthly*: Four volumes a year beginning in January, April, July, and October.

**Correspondence concerning business matters should be addressed to:** Customer Service, Subscriptions, Williams & Wilkins, 351 West Camden Street, Baltimore, MD 21201-2436. Telephone 1-(800) 638-6423 from anywhere in the U.S. and Canada. From other countries, call (410) 528-8555. Fax: (410) 528-8596.

**Correspondence regarding editorial matters should be addressed to the Editor:** Dr. John A. Harvey, Editor in Chief, Journal of Pharmacology and Experimental Therapeutics, Medical College of Pennsylvania and Hahnemann University, EPPI Conference Center, Suite 505D, 3200 Henry Avenue, Philadelphia, PA 19129. Telephone: (215) 842-4061 Fax: (215) 843-0690. E-mail: JPET@MEDCOLPA.EDU.

**For information on Society membership, contact:** The American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814. Telephone (301) 530-7060 Fax: (301) 530-7061.

**Instructions to Authors** appears in the first issue of each volume (January, April, July, October).

**Annual Subscription Rates:** U.S.: *Personal* \$190.00; *Institutional* \$370.00; *Single copy* \$33.00. **Outside the U.S., except for Japan:** *Personal* \$265.00; *Institutional* \$445.00; *Single copy* \$39.00.

**Institutional (multiple reader) rate** applies to libraries, schools, hospitals, clinics, group practices, and federal, commercial and private institutions and organizations.

**For Japanese rates, please contact:** Igaku-Shoin MYW Ltd., 3-23-14 Hongo, Bunkyo-Ku, Tokyo 113, JAPAN. Telephone: (03) 5689-5400 or 5401. Fax: (03) 5689-5402.

PRICES ARE SUBJECT TO CHANGE.

The GST number for Canadian subscribers is 123394371. Country of origin USA.

**New subscriptions** received before May 1st of each year will begin with the first issue of the year. Subscriptions received between May 1st and October 31st will start with the mid-year issue (July). Subscriptions received after October 31st will start with the first issue of the following year. Subscriptions may start with any current volume's issue upon request.

**Renewals** should be done *promptly* to avoid a break in journal

delivery. The Publisher cannot guarantee to supply back issues on late renewals.

**Change of address:** The publisher must be notified 60 days in advance. Journals undeliverable because of incorrect address will be destroyed. Duplicate copies may be obtained, if available, from the Publisher at the regular price of a single issue. Send address changes to THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 351 West Camden Street, Baltimore, MD 21201-2436. **If a member**, please contact the Society with your change.

**Reprints of individual articles** are available only from the authors.

**Reprints in large quantities**, for commercial or academic use, may be purchased from the Publisher. For information and prices call (410) 528-4292.

**Microfilm and Microfiche:** Prices are available upon request. Microfilm editions may be ordered from Williams & Wilkins.

**The Journal subscription list** is available for rental on a controlled basis from Williams & Wilkins. All promotional literature must be approved in advance.

**Disclaimer:** The statements and opinions contained in the articles of THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS are solely those of the individual authors and contributors and not of the American Society for Pharmacology and Experimental Therapeutics or Williams & Wilkins. The appearance of advertisements in the Journal is not a warranty, endorsement or approval of the products or safety. The American Society for Pharmacology and Experimental Therapeutics and the Publisher disclaim responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.

**Volume indices** appear in the March, June, September, and December issues.

**Indexing/Abstracting Services:** The Journal is currently included by the following services in print and/or electronic format: *Index Medicus*, *Current Contents (Life Sciences, Science Citation Index, Research Alert [personalized search service], ISI/BioMed [on-line database], Excerpta Medica*, and *Bio-sciences Information Service*, and *Reference Update/Research Information Systems*.

**Copyright Information:** THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS is copyrighted by the American Society for Pharmacology and Experimental Therapeutics. No portion(s) of the work(s) may be reproduced without written consent from Williams & Wilkins. Permission to reproduce copies of articles for non-commercial use may be obtained from the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923, (508) 750-8400, with a fee of \$3.00 per copy.

Copyright © 1996 by the American Society of Pharmacology and Experimental Therapeutics.

The top ranking journal in the field...

# Pharmacological

A Publication of the American Society for  
Pharmacology and Experimental Therapeutics, Inc.

## REVIEWS

**David B. Bylund, PhD, Editor**  
*University of Nebraska Medical Center*

**P**harmacological Reviews is a show-case for important review articles in your field, featuring longer papers on topics of high current interest.

Topics covered in review papers have included biochemical and cellular pharmacology, drug metabolism and disposition, renal pharmacology, neuropharmacology, behavioral pharmacology, clinical pharmacology, and toxicology. No library serving the pharmacologic community should be without a subscription.



**Published Quarterly**

❖  
Discounts available to members on all  
ASPET publications.

Save 10% when ordering two publications

Save 15% when ordering three publications

Save 20% when ordering all four publications

❖

Please enter my subscription to **Pharmacological Reviews**.

- ☐ Individual \$65/year  
☐ Institutional \$115/year  
☐ In-training\* \$50/year  
(add \$20/year outside the U.S.; in Canada also add 7% GST)  
☐ New Subscription ☐ Renewal

Subscribe for: ☐ 3 years ☐ 2 years ☐ 1 year

Name \_\_\_\_\_

Address \_\_\_\_\_

City/State/Zip \_\_\_\_\_

\* Please indicate institution/status \_\_\_\_\_

PTS 56641

Printed in USA

#### Payment Options:

- ☐ Check enclosed (payable to Williams & Wilkins)  
☐ Bill me ☐ American Express ☐ MasterCard ☐ VISA  
Card # \_\_\_\_\_ Exp. date \_\_\_\_\_

Signature or P.O. # \_\_\_\_\_  
MD, ME, and IL subscribers must add state sales tax. Subscriptions outside the U.S. must be prepaid in U.S. dollars. In Japan, contact Igaku-Shoin, MYW, Ltd. (03) 5689-5400. Rates valid through October 31, 1996.

Return coupon to:  
**Williams & Wilkins**  
A WAVERLY COMPANY

P.O. Box 23291, Baltimore, MD 21203-9990



For credit card orders, call TOLL FREE: 1-800-638-6423 in North America; outside North America, fax 1-410-361-8048 or call one of our international offices: Tokyo (03) 5689-5400, London 0171-385-2357, Hong Kong 852-2610-2339.



S6J046Z



# AUTHOR INDEX

- Abboa-Offei, B. E., 708  
 Abe, Y., 433  
 Abi-Younes, S., 652  
 Adler, A. L., 473  
 Agnati, L. F., 795  
 Ali, H., 837  
 Alkana, R. L., 667  
 Asaad, M. M., 708  
 Baez, M., 720  
 Baraldi, P. G., 398  
 Barker, L. A., 500  
 Barnette, M. S., 810  
 Barrett, R. J., 490  
 Basbaum, A. I., 801  
 Bauman, J. L., 568  
 Beaven, M. A., 837  
 Beck, G., 609  
 Bejanian, M., 667  
 Belknap, J. K., 532  
 Bhatt, R. K., 728  
 Bigelow, G. E., 449  
 Bitar, K. N., 714  
 Blier, P., 697  
 Bolger, M. B., 667  
 Bonhomme, M., 637  
 Bottorff, M. B., 683  
 Boundy, V. A., 784  
 Breese, G. R., 482  
 Brett, C. M., 676  
 Bril, A., 637  
 Brinton, R. D., 667  
 Calzadilla, S. V., 473  
 Campbell, I. G., 737  
 Capasso, A., 743  
 Catlow, J., 658  
 Cella, S. G., 795  
 Cerimele, B. J., 658  
 Chan, C. K. S., 411  
 Chen, F. Y., 353  
 Chéramy, A., 616  
 Chiba, S., 467  
 Chiou, W. J., 473  
 Choi, O. H., 837  
 Chou, C., 855  
 Chung, S.-J., 676  
 Ciceri, S., 795  
 Cieslinski, L. B., 810  
 Cipris, S., 690  
 Coe, I. R., 365  
 Constantinescu, A., 365  
 Conti, A., 398  
 Cook, S. A., 585  
 Correa, L. D., 509  
 Cotreau-Bibbo, M. M., 370  
 Criswell, H. E., 482  
 Cumming, P., 500  
 Daaka, Y., 776  
 Dalby, N. O., 516  
 Daniel, E. E., 690  
 Davies, D. L., 667  
 Davis-Cox, M. I., 758  
 Dayton, B. D., 473  
 De Gennaro Colonna, V., 795  
 De Marco, A., 795  
 Diamond, I., 365  
 Di Giannuario, A., 743  
 Dingaan, B., 652  
 Dionisotti, S., 398  
 Dixon, D. B., 473  
 Dohrman, D. P., 365  
 Dorso, C. R., 708  
 Duan, S. X., 370  
 Dunlop, J. L., 509  
 Dykstra, L. A., 626  
 Eddy, E. P., 609  
 Ehler, F. J., 405  
 Eissenberg, T., 449  
 Ellens, H., 609  
 Elliott, J. D., 609  
 Faivre, J.-F., 637  
 Falck, J. R., 728  
 Farhat, M. Y., 652  
 Fecho, K., 626  
 Feinberg, I., 737  
 Fletcher, T. L., 758  
 Fong, K.-L., 609  
 France, C. P., 523  
 Franklin, M. R., 602  
 Fraundorfer, P. F., 837  
 Friedman, H., 776  
 Fukuda, M., 765  
 Fukuyama, S., 421  
 Furukawa, Y., 467  
 Galinsky, R. E., 602  
 Gargalidis-Moudanos, C., 359  
 Gehrke, L. J., 473  
 Gerak, L. R., 523  
 Giacomini, K. M., 676  
 Gillespie, T., 658  
 Glennon, R. A., 594  
 Glowinski, J., 616  
 Godeheu, G., 616  
 Gogas, K. R., 801  
 Gonzaga, H. M. S., 837  
 Gordon, A. S., 365  
 Gout, B., 637  
 Gravel, S., 728  
 Greenblatt, D. J., 370  
 Greene, J. R. T., 426  
 Greenwald, M. K., 449  
 Griffin, M. T., 405  
 Grover, G. J., 380  
 Hamman, M. A., 658  
 Hariman, R. J., 568  
 Harmatz, J. S., 370  
 Harrel, L. M., 370  
 Hasegawa, T., 460  
 Hashemi, M., 728  
 Hashmi, M., 770  
 Hay, D. W. P., 609  
 Haynes, J., Jr., 752  
 Head, G. A., 411  
 Heidebreder, C., 545  
 Hernandez, L., 473  
 Hirasawa, Y., 421  
 Hough, L. B., 500  
 Hoyano, Y., 467  
 Imamura, H., 467  
 Ishine, T., 353  
 Ishisu, R., 433  
 Jacoby, H. I., 647  
 Johnson, R. E., 449  
 Kasama, M., 467  
 Kato, M., 421  
 Kato, Y., 421  
 Kest, B., 532  
 Khanapure, S. P., 728  
 Killilea, D. W., 752  
 Kita, Y., 421  
 Klein, T. W., 776  
 Kleven, M. S., 388  
 Koek, W., 388  
 Komori, Y., 460  
 Kothary, P. C., 714  
 Kothary, S., 714  
 Kursar, J. D., 720  
 Lago, A., 609  
 Lai, C. C., 353  
 Landais, L., 637  
 Lee, T. J.-F., 353  
 LeFevour, A., 545  
 Levine, J. D., 801  
 Lew, R., 846, 855  
 L'hirondel, M., 616  
 Li, B. Y., 500  
 Lichtman, A. H., 585  
 Liebson, I. A., 449  
 Limon-Boulez, I., 359  
 Linden, J., 490  
 Lindsay, T. J., 658  
 Linee, P., 637  
 Liu, D., 568  
 Livi, G. P., 810  
 Lloyd, G. K., 509  
 Loizzo, A., 743  
 Lu, L., 784, 819  
 Lucaites, V. L., 720  
 Luo, J., 819  
 Lysle, D. T., 626  
 MacLeod, R. J., 728  
 Maeda, K., 765  
 Magnuson, S. R., 473  
 Manna, S., 728  
 Manning, C. D., 810  
 Markel, M. L., 683  
 Marsh, K. C., 473  
 Martin, B. R., 585  
 Martin, P. L., 490  
 Maslonek, K. A., 626  
 Mason, A., 426  
 May, J. M., 490  
 Mayeux, P. R., 555  
 McGonigle, P., 819  
 McLaughlin, M. M., 810  
 Meijer, D. K. F., 561  
 Menzaghi, F., 509  
 Mitroka, J. G., 380  
 Mogil, J. S., 532  
 Molinoff, P. B., 784  
 Monopoli, A., 398  
 Mørland, J., 667  
 Moseley, R. H., 561  
 Muller, E. E., 795  
 Munir, M., 819  
 Nabeshima, T., 460  
 Nakahata, N., 829  
 Nakano, H., 467  
 Nakano, T., 433  
 Nalwalk, J. W., 500  
 Nambi, P., 609  
 Narimatsu, A., 433  
 Negretti, A., 398  
 Nelson, D. L., 720  
 Nikai, T., 460  
 Nishino, S., 421  
 Noda, Y., 460  
 Novosad, E. I., 473  
 Ohizumi, Y., 829  
 Ohkubo, K., 421  
 Ohlstein, E. H., 609  
 Ohno, M., 421  
 Oliff, H. S., 405  
 Ongini, E., 398  
 Onishi, K., 433  
 Ono, H., 829  
 Oppenorth, T. J., 473  
 Parham, C. S., 380  
 Parini, A., 359  
 Parker, E. S., 667  
 Parsons, M. E., 500  
 Pasyk, E. A., 690  
 Peterson, P. D., 752  
 Pieretti, S., 743  
 Piñeyro, G., 697  
 Powell, W. S., 728  
 Poyser, R. H., 637  
 Pritchard, G. A., 370  
 Proksch, J. W., 555  
 Raffa, R. B., 647  
 Raftogianis, R. B., 602  
 Ramanathan, V. K., 676  
 Ramwell, P. W., 652  
 Richards, J., 855  
 Richards, J. B., 846  
 Ring, B. J., 658  
 Rogers, W. L., 708  
 Rokach, J., 728  
 Roll, K., 683  
 Rosebrough, S. F., 770  
 Roskos, L. K., 658  
 Ruffolo, R. R., Jr., 637  
 Sabol, K. E., 846, 855  
 Sacca, A. I., 509  
 Sadowski, B., 532  
 Sagratella, S., 743  
 Sakai, K., 829  
 Sannajust, F., 411  
 Sarwinski, S., 353

Schupsky, J. J., 647	Sorrentino, L., 743	Traylor, L. A., 555	Whigan, D. B., 380
Schur, M., 683	Stevens, C. W., 440	Turner, J. N., 758	Winn, M., 473
Seiden, L. S., 846, 855	Stewart, J., 683	Ujhelyi, M. R., 683	Wolfe, B. B., 819
Seki, J., 421	Stitzer, M. L., 449	van Solkema, B. G. H., 561	Wright, C. E., 370
Sekioka, K., 433	Sugihara, H., 460	Vargas, R., 652	Wrighton, S. A., 658
Settembrini, B. P., 795	Swanson, S. P., 658	von Geldern, T. W., 473	Wysocki, R. J., Jr., 490
Seymour, A. A., 708	Szarowski, D., 758	von Moltke, L. L., 370	Yamada, K., 460, 837
Shader, R. I., 370	Sze, P. Y., 578	Vosmer, G. L., 846, 855	Yamamoto, T., 829
Shain, W., 758	Takamatsu, H., 421	Wainscott, D. B., 720	Yang, X., 482
Shippenberg, T. S., 545	Tesson, F., 359	Wang, W., 561	Young, R., 594
Smit, H., 561	Thompson, W. J., 752	Wang, Y.-H., 819	Zhang, H., 683
Smith, P., 609	Thomsen, C., 516	Wessale, J. L., 473	Zocchi, C., 398
Smith, P. L., 708	Torphy, T. J., 810	Whelan, K. T., 509	Zoli, M., 795